Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac174
Abstract: Abstract Pfizer and the Medicines Patent Pool (MPP) have reached a voluntary licensing agreement for Paxlovid (nirmatrelvir+ritonavir), a novel antiviral for coronavirus disease 2019 (COVID-19) taken orally in the first 5 days from symptom onset.… read more here.
Keywords: paxlovid; barriers worldwide; mpp deal; worldwide access ... See more keywords
CYP induction to reverse tacrolimus toxicity resulting from concomitant Paxlovid use
Sign Up to like & getrecommendations! Published in 2022 at "Transplant Infectious Disease"
DOI: 10.1111/tid.13982
Abstract: To the Editor We have seen the devastation the SARS-CoV-2 (COVID-19) virus has caused on the population worldwide. As of writing this paper, there have been almost 6.5 million deaths from this virus to date.1… read more here.
Keywords: paxlovid; toxicity; cyp induction; tacrolimus ... See more keywords
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Toxicology"
DOI: 10.1177/10915818221095489
Abstract: COVID-19 is a potentially fatal infection caused by the SARS-CoV-2 virus. The SARS-CoV-2 3CL protease (Mpro) is a viral enzyme essential for replication and is the target for nirmatrelvir. Paxlovid (nirmatrelvir co-administered with the pharmacokinetic… read more here.
Keywords: paxlovid; safety; pharmacology; development ... See more keywords